SecBot SecBot
8-K ·Filed Mar 5, 2026

CTNM

Contineum Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed8mo ago SEC0001628280-26-015159
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming topline data from the chronic pain Phase 1b trial expected in Q2 2026 and progress in the IPF Phase 2 trial. The increased ATM capacity provides funding flexibility but could lead to future dilution.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.88
T+0 close · Mar 5, 2026 · via day close
Latest settled
−5.69%
T+60 · $13.09
Vs SPY
−18.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 6 $13.88entry
  2. T+1 · 8mo ago −2.45%α −3.30% · $13.54
  3. T+5 · 8mo ago −6.34%α −4.81% · $13.00
  4. T+20 · 8mo ago −3.17%α −1.13% · $13.44
  5. T+60 · 6mo ago −5.69%α −18.47% · $13.09
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Contineum Therapeutics reported Q4 2025 financial results showing a net loss of $15.2 million and research and development expenses of $12.8 million. The company raised $93 million in a public offering and increased its at-the-market (ATM) equity offering capacity from $75 million to $100 million. They initiated patient dosing in a Phase 2 trial for IPF and expect topline data from a chronic pain trial in Q2 2026. With $262.9 million in cash, they project runway into mid-2029.

Key Financial Metrics

EPS
$-0.49

Key Facts

  • Net loss of $15.2 million for Q4 2025, compared to $14.6 million in Q4 2024
  • Cash, cash equivalents, and marketable securities totaled $262.9 million as of December 31, 2025
  • Completed public offering generating $93 million in net proceeds
  • Increased ATM equity offering capacity from $75 million to $100 million
  • Initiated patient dosing in PROPEL-IPF Phase 2 trial for idiopathic pulmonary fibrosis
  • Projected cash runway extends into mid-2029

Financial Impact

Cash increased to $262.9 million after $93 million public offering; R&D expenses decreased 2% to $12.8 million

cashr&d expensesnet loss

Risk Factors

  • Biotech stocks are inherently volatile with binary outcomes based on clinical trial results
  • Increased ATM capacity could lead to significant share dilution if utilized
  • Company remains in clinical stage with no approved products, dependent on successful trial outcomes

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-015159
Document: ctnm-20260305.htm0001628280-26-015159
Document: a2026_marchx8kxex-11.htm0001628280-26-015159
Document: a2026_marchx8kxex-51.htm0001628280-26-015159
Document: 0001628280-26-015159-index-headers.html0001628280-26-015159
Document: 0001628280-26-015159-index.html0001628280-26-015159
Document: 0001628280-26-015159.txt0001628280-26-015159

US Market Status

Market Closed · Opens in 6h 54m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026